GlassScriptPhysician profile
Rachel Bernard
NPI 1578335469
$3,990.70
in general payments reported to CMS, 2019-2025
32 companies · $3,010 in 2025
The $3,010 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $981 · 2025: $3,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,990.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.52 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.71 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $391.21 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $295.25 | 2024-2025 | Zoryve |
| Amgen INC. | $231.94 | 2024-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $226.48 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $213.66 | 2024-2025 | |
| Lilly USA, LLC | $199.78 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $154.84 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Qol Medical, LLC | $120.32 | 2025 | Sucraid |
| Exact Sciences Corporation | $119.24 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $104.04 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $101.40 | 2024-2025 | Austedo Xr, Ajovy |
| Lundbeck LLC | $96.13 | 2025 | Rexulti |
| Eisai INC. | $81.67 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.90 | 2024-2025 | Jardiance |
| Almatica Pharma LLC | $70.22 | 2024-2025 | Loreev Xr |
| Corcept Therapeutics | $53.19 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $52.49 | 2025 | Trintellix |
| Optinose US, INC. | $50.91 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.89 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $44.24 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $42.04 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $36.02 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $30.23 | 2024-2025 | Contrave |
| Dexcom, INC. | $24.77 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $23.78 | 2025 | Inspire |
| Bausch Health US, LLC | $23.09 | 2024 | Aplenzin |
| Beta Bionics, INC. | $20.22 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $15.65 | 2025 | Unithroid |
| Esperion Therapeutics, INC. | $15.15 | 2025 | Nexletol |
| Shield Therapeutics INC | $13.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.